Celiac Disease Market 2023: Opportunity Analysis and Forecast

"The Report OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Celiac Disease Market

There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population. GlobalData estimates that the uptake of both drugs will be equally high, but latiglutenase will rapidly gain market value and emerge the commercially stronger drug with the backing of Immune-Gastro veteran AbbVie.

Highlights

Key Questions Answered

(Q.) How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM?
(Q.) What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market?
(Q.) How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?
(Q.) What are the significant unmet needs in the celiac disease market?
(Q.) What are the remaining opportunities in the celiac disease market?

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/244452

Key Findings

High uptake is expected of pipeline drugs for celiac disease that are anticipated to launch during the 2013-2023 forecast period.
Celiac disease remains a field of highly unattained unmet need.
There is no consensus over clinical trial design and endpoints for the development of celiac disease products.
The clinical stage pipeline is mainly focussed on GFD adjunctive therapies, while the pre-clinical stage pipeline has shifted its focus to disease modifying treatments.
Significant opportunity exists for products targeting in the non-refractory patient segment of the celiac disease market.
M&A’s and alliance opportunities will be key factors in driving celiac disease drug development.

Scope

Overview of celiac disease, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
Annualized celiac disease therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018 and ten years to 2023.
Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the celiac disease therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including zonulin inhibitors, gluten peptide enzymes, gluten specific synthetic polymers and therapeutic vaccines.
Analysis of the current and future market competition in the US and five major EU celiac disease therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.
Reasons to buy

View Full Report @ https://www.marketresearchreports.biz/reports/244452/opportunityanalyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023-market-research-reports

The report will enable you to
Identify the unmet needs and remaining opportunities in the celiac disease therapeutics market.
Develop business strategies by understanding the trends shaping and driving the US and five major EU celiac disease therapeutics market.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Assess the clinical and commercial viability of promising pipeline products.
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU celiac disease therapeutics market in future.

Table of Contents

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 16

2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 18
2.3 Upcoming Related Reports 18

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/244452

3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.2 Prognosis and Quality of Life 21
3.3 Symptoms 22

4 Epidemiology 24
4.1 Disease Background 24
4.2 Risk Factors and Comorbidities 24
4.3 Global Trends 27
4.3.1 US 30
4.3.2 5EU 30
4.4 Forecast Methodology 31
4.4.1 Sources Used 32
4.4.2 Sources Not Used 35
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of Celiac Disease 37
4.4.4 Forecast Assumptions – Diagnosed Prevalent Cases of Celiac Disease 40
4.5 Epidemiological Forecast for Celiac Disease (2013–2023) 41
4.5.1 Total Prevalent Cases of Celiac Disease 41
4.5.2 Age-Specific Total Prevalent Cases of Celiac Disease 43
4.5.3 Sex-Specific Total Prevalent Cases of Celiac Disease 44
4.5.4 Age-Standardized Total Prevalence of Celiac Disease 46
4.5.5 Diagnosed Prevalent Cases of Celiac Disease 47
4.6 Discussion 49
4.6.1 Epidemiological Forecast Insight 49
4.6.2 Limitations of the Analysis 50
4.6.3 Strengths of the Analysis 51

5 Current Treatment Options 52
5.1 Overview 52
5.2 Product Profiles – Major Therapies 57
5.2.1 Steroids (Numerous Brands and Generic Names) 57
5.2.2 Immunosuppressants (Azathioprine) 63

6 Unmet Need and Opportunity 68
6.1 Overview 68
6.2 Reliable Diagnosis 71
6.2.1 Unmet Need 71
6.2.2 Gap Analysis 72
6.2.3 Opportunity 72
6.3 Improved Physician Knowledge of Celiac Disease Diagnosis 73
6.3.1 Unmet Need 73
6.3.2 Gap Analysis 74
6.3.3 Opportunity 75
6.4 Increased Patient Awareness of a Gluten-Free Diet 76
6.4.1 Unmet Need 76
6.4.2 Gap Analysis 77
6.4.3 Opportunity 78
6.5 Lack of Approved Pharmacological Therapies 78
6.5.1 Unmet Need 78
6.5.2 Gap Analysis 80
6.5.3 Opportunity 80
6.6 Improved Compliance to a Gluten-Free Diet 81
6.6.1 Unmet Need 81
6.6.2 Gap Analysis 81
6.6.3 Opportunity 82
6.7 Improved Therapies for Refractory Celiac Disease Type I 82
6.7.1 Unmet Need 82
6.7.2 Gap Analysis 83
6.7.3 Opportunity 83
6.8 Available Therapies for Refractory Celiac Disease Type II 83
6.8.1 Unmet Need 83
6.8.2 Gap Analysis 84
6.8.3 Opportunity 85

7 R&D Strategies 86
7.1 Overview 86
7.1.1 Development of Pharmacological Interventions with Novel MOAs 86
7.1.2 Diverse Preclinical Research 87
7.1.3 Licensing and Alliances 88
7.2 Clinical Trial Design 89
7.2.1 No Standardized Clinical Trial Design Exists in Celiac Disease 89
7.2.2 Trial Outcome Measures are Tailored to the Pipeline Drug Being Investigated 90
7.2.3 Trial Designs for Early-Stage Pipeline Drugs Likely to be Dictated by Their MOA 90

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.